Immunotherapy Added to Chemotherapy for Relapsed Hodgkin Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding a type of immune-boosting drug (called checkpoint inhibitor immunotherapy) after high-dose chemotherapy and stem cell transplant helps people with Hodgkin lymphoma that has returned or didn't respond to initial treatment. The goal is to see if this combination works better than chemotherapy and transplant alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Biopsy-confirmed Hodgkin lymphoma that came back or didn't respond to your first round of chemotherapy
- Age 5–75 years old, in reasonable overall health (able to do light daily activities)
- Recent imaging (PET scan or MRI) within 56 days showing your cancer has returned, done before starting any new cancer treatment
- Meet 'high-risk' criteria: cancer came back very quickly (within 3–6 months), in many places, or involves bone marrow; OR medically eligible for high-dose chemotherapy and stem cell transplant
- Adequate blood counts, liver function, and kidney function (checked within 14 days of enrollment)
- Not pregnant or breastfeeding, and willing to use reliable contraception during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests brentuximab and nivolumab (two anti-cancer medicines) in people with classical Hodgkin lymphoma that has come back or did not respond to earlier treatment. It may help by attacking lymphoma cells in different ways, especially after limited options from prior therapies.
This trial tests a combination of two medicines—azacitidine and a PD-1 inhibitor—for people with Hodgkin lymphoma that has returned or not responded to previous treatment. The aim is to see if this combination can help control the disease.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial uses a blood test (ctDNA) to guide treatment for Hodgkin lymphoma that has come back or not responded to one prior treatment. You would receive a combination of drugs (pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin) to see if it works better.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Hear when a new Refractory Classic Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.